Privi Q3 FY26 results, Rs 25.5 Cr investment in subsidiary Prigiv

Revenue DeclineRelated Party TransactionsResults View source PDF Explain this filing

PRIVISCL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.1%Reaction day

₹2754.90

prior close

₹2700.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+1.0%-2.1% vs market

Specialty Chemicals peers, median of 87sector+0.4%-1.4% vs sector

On the reaction day the stock moved 2.1 pts less than Nifty Microcap 250 and 1.4 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.8

10m

+1.2

15m

+1.3

30m

+1.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.1+1.0-2.1+0.4-1.4

Next day

-0.0+0.5-0.5+0.4-0.4

+1.7-0.0+1.7-0.3+2.0

-1.3-1.5+0.2-2.1+0.8

+2.0-2.2+4.2-3.4+5.4

+3.1-1.2+4.3-3.1+6.2

+5.2-2.4+7.5-3.3+8.4

15d

+3.7-8.8+12.6-11.3+15.1

+6.6-8.3+14.9-9.9+16.5

+5.3-3.5+8.8-5.8+11.1

+26.4+6.4+20.0+3.8+22.6

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 87Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q3 and 9M FY26 results. Standalone Q3 revenue was nearly flat at Rs 252.7 Cr versus Rs 253.9 Cr YoY, while PAT rose to Rs 39.5 Cr from Rs 27.8 Cr. Nine-month revenue fell to Rs 837.8 Cr from Rs 931.4 Cr; nine-month PAT was Rs 39.1 Cr versus Rs 47.6 Cr. Also approved Rs 25.5 Cr equity infusion in Prigiv Specialties, a subsidiary and JV with Givaudan SA, maintaining 51 percent stake. Auditor gave an unmodified review.

Likely market impact

9M revenue declined YoY but Q3 PAT improved. Rs 25.5 Cr subsidiary investment signals capacity expansion with Givaudan JV.